RxDoctor Payments Data

Hector Rosado Toledo, MD

Pulmonary Disease · Ponce, PRNPI 1851339717

Payments from drug & device makers

$2,830in general payments, 2019–2025

Across 83 payments — averaging $34.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$988
  • AstraZeneca$424
  • Boehringer Ingelheim$323
  • United Therapeutics Corporation$256
  • Grifols USA, LLC$177
  • E.r. Squibb & Sons, L.L.C.$128
  • plus $535 from 7 others

What the payments were for

  • Food & beverage$2,825100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK24$988
AstraZeneca32$424
Boehringer Ingelheim8$323
United Therapeutics Corporation5$256
Grifols USA, LLC1$177
E.r. Squibb & Sons, L.L.C.2$128
Bayer2$127
Pfizer Pharmaceuticals LLC1$124
Gilead4$88
Genentech USA, Inc.1$67
Jazz Pharmaceuticals Inc.1$63
Merck1$60
PBG Puerto Rico LLC1$6

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,830 in reported general payments places this provider in the 55th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$5,674
Medicare patients
19
Services billed
65

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat86$1,197,522
OpsumitMacitentan46$582,670
Breo ElliptaFluticasone/Vilanterol337$138,871
Trelegy ElliptaFluticasone/Umeclidin/Vilanter108$71,736
AdcircaTadalafil11$45,962
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr77$36,706
Stiolto RespimatTiotropium Br/Olodaterol Hcl70$36,311
Spiriva HandihalerTiotropium Bromide23$12,773
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate38$10,862
SymbicortBudesonide/Formoterol Fumarate41$9,796
Wixela InhubFluticasone Propion/Salmeterol38$5,964
Spiriva RespimatTiotropium Bromide11$5,907
Prednisolone Sodium Phosphate233$4,713
Fluticasone Propionate158$2,711
Clorazepate Dipotassium23$2,154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerAdempas$127$1,197,52286 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$988$247,312522 claims
United Therapeutics CorporationAdcirca$256$45,96211 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$323$42,21881 claims
AstraZenecaSymbicort$424$9,79641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →